New in Cephalalgia!
In real-world practice, CGRP monoclonal antibodies substantially reduce migraine frequency, but achieving optimal migraine control remains challenging, particularly in patients with higher baseline migraine burden.
https://t.co/vrLdFAQNcz
#migraine#headache #brain #pain #neurology #neuroscience
New in Cephalalgia!
This systematic review and meta-analysis provide robust evidence on the effect of angiotensin II receptor blockers (ARBs), particularly candesartan, in the prevention of episodic migraine, supporting the rationale for reconsidering its position in international guidelines.
https://t.co/5faa4tUpRP
#migraine #headache #brain #pain #neurology #neuroscience
@norhead
𝗦𝘂𝗴𝗴𝗲𝘀𝘁𝗲𝗱 𝗥𝗲𝘃𝗲𝗿𝘀𝗮𝗹 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗼𝗳 𝗢𝗿𝗮𝗹 𝗔𝗻𝘁𝗶𝗰𝗼𝗮𝗴𝘂𝗹𝗮𝗻𝘁 𝗨𝘀𝗲 𝗳𝗼𝗿 𝗠𝗮𝗷𝗼𝗿 𝗕𝗹𝗲𝗲𝗱𝗶𝗻𝗴 𝗮𝗻𝗱 𝗯𝗲𝗳𝗼𝗿𝗲 𝗘𝗺𝗲𝗿𝗴𝗲𝗻𝗰𝘆 𝗦𝘂𝗿𝗴𝗲𝗿𝘆.
As shown in Panel A, reversal management depends on the urgency of surgery or the invasive procedure. Reversal management includes administration of oral or intravenous (IV) vitamin K with or without 4F-PCC, depending on the timing of the procedure (emergency or urgent), baseline international normalized ratio (INR) value, and presence (or absence) of active bleeding. For patients receiving direct oral anticoagulants (DOACs), the decision also depends on time to surgery. Decision making is informed by DOAC type, time since last dose, half-life, presence (or absence) of active bleeding, and renal function tests to estimate residual drug activity.
Panel B shows reversal strategies for patients presenting with major bleeding while receiving an oral anticoagulant. The reversal strategy of vitamin K antagonists includes vitamin K given intravenously or orally, combined with 4F-PCC and INR testing. Management of anticoagulant reversal of direct oral FXaIs is based on four key factors (shown as the 4Ts): type of bleeding, timing of the last dose, thrombotic risk, and need for invasive procedures in the next 48 hours that would result in the administration of UFH. These factors may facilitate the use of specific (e.g., andexanet alfa) or nonspecific (e.g., 4F-PCC) antidotes. The reversal of dabigatran is informed by three clinical variables (shown as the 3Rs) — the type of bleeding, time of the last dose of dabigatran, and preserved renal function.
Learn more in the Review Article “Antidotes for Anticoagulation Reversal” by Bianca Rocca, MD, PhD, and Hugo ten Cate, MD, PhD: https://t.co/XobqwMebfy
NEJM subscribers: Explore this article deeper with AI Companion.
ข่าวใหญ่วงการ medical AI ผลวิจัยลงใน Nature Medicine พบว่า general purpose models อย่าง Opus, GPT, Gemini เก่งกว่า clinical AI ในทุกการทดสอบ แถมยัง hallucinate น้อยกว่าด้วย
การพัฒนาของ frontier models ใหญ่ไปไกลและเร็วกว่า niche models มากจนเจ้าเล็กตามไม่ทันแล้ว ยุคของ medical AI model ต่อจากนี้ต้องเน้น use case และการ integrate กับ workflow เป็นหลัก ขายจุดแข็งเรื่องความฉลาดไม่ได้อีกต่อไป
https://t.co/PnceUNkhc3
Excellent paper on Cerebellar ataxia with chorea....genetic etiologies & key points for diagnosis & management..
🧩🪬Always look for treatable/ reversible causes first...
@MichaelOkun@MDCP_Journal
https://t.co/2jSPrIaBV9
#STROKE: This topical review by @AJagolinoCole et al. discusses the origins of vascular neurology training and current challenges in sustaining educational programs. https://t.co/AYiAAIsqyO